Search

Your search keyword '"Immunoglobulin G -- Evaluation"' showing total 6 results
Start Over Descriptor "Immunoglobulin G -- Evaluation"
6 results on '"Immunoglobulin G -- Evaluation"'

1. Raxibacumab for the treatment of inhalational anthrax

Author

Migone, Thi-Sau, Subramanian, G. Mani, Zhong, John, Healey, Letha M., Corey, Al, Devalaraja, Matt, Lo, Larry, Ullrich, Stephen, Zimmerman, Janelle, Chen, Andrew, Lewis, Maggie, Meister, Gabriel, Gillum, Karen, Sanford, Daniel, Mott, Jason, and Bolmer, Sally D.

Subjects
Anthrax -- Drug therapy, Anthrax -- Prognosis, Immunoglobulin G -- Evaluation, Monkeys -- Diseases, Monkeys -- Care and treatment, Rabbits -- Care and treatment
Abstract

A study was conducted to determine the effectiveness of raxibacumab for the treatment of inhalational anthrax. Results showed that trials carried out on rabbits and monkeys with symptomative inhalational anthrax has better chances of survival following a single dose of raxibacumab.

Published
2009

2. Clinical Relevance of CagA-specific Antibodies Related to CagA Status of Heliobacter pylori Isolates Using Immunofluorescence Test and PCR

Author

Krausse, R., Garten, L., Harder, T., Ullmann, U., Birkner, T., Doniec, M., and Grimm, H.

Subjects
Fluorescent antibody technique -- Usage, Immunofluorescence -- Usage, Gastrointestinal diseases -- Diagnosis, Helicobacter pylori -- Diagnosis, Immunoglobulin G -- Evaluation, Health
Abstract

Byline: R. Krausse (1), L. Garten (1), T. Harder (1), U. Ullmann (1), T. Birkner (2), M. Doniec (2), H. Grimm (2) Keywords: Key WordsHelicobacter pylori; CagA status; Clinical relevance; Immunofluorescence; PCR; Western blot Abstract: Background: The cagA (cytotoxin-associated gene A) protein is found in about 50% of Helicobacter pylori strains its clinical relevance in gastroduodenal disease is uncertain. Patients and Methods: The frequency of IgG antibodies to cagA was studied by using a commercial Western blot assay in sera of 189 patients with endoscopically and histologically confirmed gastroduodenal disease. In addition, 38 H. pylori strains isolated from biopsies were analyzed by immunofluorescence test (IFT) and PCR for detection of cagA protein and cagA gene sequences, respectively. Results: 54.3--60.0% of all patients with gastrointestinal diseases (chronic gastritis, gastric or duodenal ulcer and chronic duodenitis) and 28.6% with a normal mucosa were found to be positive for anti-cagA IgG antibodies. There was no significant difference in anti-cagA IgG seroprevalence between the different clinical entities. CagA-positive (cagA.sup.+) H. pylori strains were detected in 44.7% and 50% of the 38 isolates by PCR and IFT, respectively. 22 of 23 patients infected with cagA.sup.+ strains had anti-cagA antibodies. Using PCR as a gold standard, the sensitivity and specificity of the cagA IgG Western blot were 100.0% and 35.0%, respectively the sensitivity and specificity of the cagA IFT were 76.5% and 71.4%, respectively. The incidence of the cagA.sup.+ H. pylori strains detected either by PCR or IFT was significantly higher (p &lt 0.05 and p &lt 0.01, respectively) in patients with chronic duodenitis, gastric or duodenal ulcer compared to patients with chronic gastritis (66.7%, 80% and 30.4%, respectively). Conclusion: In this study the cagA-specific serological status in H. pylori infections as diagnosed by IgG Western blot was of no predictive value for severity of disease. In contrast, the cagA status of H. pylori isolates, diagnosed by IFT or PCR, was a predictive marker for severe disease and, therefore, also of clinical relevance in the assessment of the virulence of the infecting strain. Author Affiliation: (1) Institute of Medical Microbiology and Virology University of Kiel, Brunswiker Str. 4, D-24105 Kiel, Germany Phone: (+49/431)597-3298, Fax: -3296, e-mail: r.krausse@medmicrobio.uni-kiel.de, DE (2) Dept. of Surgery, University of Kiel, Arnold-Heller Str. 7, D-24105 Kiel, Germany Phone: (+49/431) 597-4581, Fax: -4327, DE Article note: Received: July 21, 2000 * Revision accepted: March 2, 2001

Published
2001

3. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura

Author

Blanchette, Victor, Imbach, Paul, Andrew, Maureen, Adams, Margaret, McMillan, James, Wang, Elaine, Milner, Ruth, Ali, Kaiser, Barnard, Dorothy, Bernstein, Mark, Ka Wah Chan, Esseltine, Dixie, DeVeber, Barrie, Israels, Sara, Kobrinsky, Nathan, and Luke, Brian

Subjects
Immunoglobulin G -- Evaluation, Prednisone -- Evaluation, Antibodies -- Evaluation, Thrombocytopenic purpura -- Drug therapy, Brain -- Hemorrhage, Children -- Diseases
Published
1994

4. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater

Author

Dominioni, Lorenzo, Dionigi, Renzo, Zanello, Marco, Chiaranda, Maurizio, Dionigi, Roberto, Acquarolo, Annamaria, Ballabio, Andrea, and Sguotti, Chiara

Subjects
Surgery -- Complications, Immunoglobulin G -- Evaluation, Septic shock -- Drug therapy, Health
Abstract

Surgical patients who develop sepsis (contamination or poisoning of the system by bacterial infection) have a high mortality. Death usually is the result of progressive multiple organ failure or septic shock (inadequate peripheral blood flow to the heart caused by bacterial infection). Changes in the immune system have been shown to occur in severely septic patients. The blood levels of the antibody immunoglobulin G (IgG) tend to be lower in septic patients who do not survive. A study was undertaken to determine if treatment with high-dose IgG can reduce mortality among high-risk surgical patients in the intensive care unit. A standardized scoring system (developed by Elebute and Stoner) was used to evaluate the severity of the sepsis. The study included 62 consecutive patients with scores of 20 or higher; 29 patients were given IgG and 33 patients received albumin (the control group). The two patient groups were of similar age and initial sepsis scores. The mortality of the IgG-treated group was significantly lower than that of the controls: 38 versus 67 percent. The causes of death in all except one patient who had a heart attack, were septic shock and multiple organ failure. Seven percent of the IgG treated patients died from septic shock, compared with 33 percent of the control patients. These results indicate that treatment with IgG for surgical patients with high (20 or higher) sepsis scores decreases mortality due to septic shock. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

5. Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial

Author

Lawrence, Gregor, Tudehope, David, Baumann, Kathryn, Jeffery, Heather, Gill, Andrew, Cole, Michael, Drew, John, McPhee, Andrew, Ratcliffe, John, Reynolds, Graham, Simes, John, Swanson, Cheryl, Cartwright, David, Davis, Peter, Humphrey, Ian, and Berry, Andrew

Subjects
Immunoglobulin A -- Health aspects, Immunoglobulin G -- Evaluation, Drug therapy, Combination -- Usage, Enterocolitis, Neonatal necrotizing -- Prevention
Published
2001

6. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study

Author

Clapp, D. Wade, Kliegman, Robert M., Baley, Jill E., Shenker, Nancy, Kyllonen, Kay, Fanaroff, Avroy A., and Berger, Melvin

Subjects
Nosocomial infections in children -- Physiological aspects, Immunoglobulin G -- Evaluation, Infants (Premature) -- Diseases, Birth weight, Low -- Complications, Health
Abstract

Premature infants are at risk for infection. They are born with low blood levels of immunoglobulin-G (IgG), as this antibody is transferred through the placenta during the last trimester of pregnancy. These already low levels decrease even further during the first three months of life. IgG has been administered to premature newborns in order to prevent infection. A pilot study was designed to evaluate the effectiveness of intravenous IgG (IVIG) in the prevention of nosocomial (hospital-associated) infection. In this prospective study, 115 patients were randomly assigned to either a treatment or control group. A third group of 85 infants, not included in the study at parental request, were followed and analyzed separately. The birth weights ranged from 600 to 2000 grams (one lb five oz to four lbs six oz) and gestational age was 30 to 31 weeks. The infants in the treatment group were administered IVIG in doses to maintain a blood level of IgG at approximately 700 mg/dl. Infections occurred in seven of the control group and nine of the nonparental consent group. No infections occurred in the IVIG treatment group. All babies in the control group who developed infection were found at that time to have IgG blood levels of 400 mg/dl or less. One patient in the treatment group developed rapid heart beat during IVIG, which disappeared when the IVIG was discontinued. These data suggest that maintaining a therapeutic (700 mg/dl) level of IgG in the blood during hospitalization may decrease the incidence of nosocomial infection in low-birth-weight babies.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results